Cargando…

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%: Retraction

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Retraction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824688/ https://www.ncbi.nlm.nih.gov/pubmed/31651909 http://dx.doi.org/10.1097/MD.0000000000017868

Ejemplares similares

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%
por: Zhao, Mingyue, et al.
Publicado: (2019)

Retracted: Clinical Study of Heart Failure with Left Ventricular Ejection Fraction Regimen Treated with Entresto
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Left ventricular contractile performance and heart failure in patients with left ventricular ejection fraction more than 40%
por: Kitada, Shuichi, et al.
Publicado: (2020)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Retraction: differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction—results of a meta-analysis of randomized controlled trials
Publicado: (2023)

Impact of angiotensin receptor–neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study
por: Nathaniel, Sangeetha, et al.
Publicado: (2022)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Reverse electrical remodeling in rats with heart failure and preserved ejection fraction
por: Cho, Jae Hyung, et al.
Publicado: (2023)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
por: Poglajen, Gregor, et al.
Publicado: (2020)

Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
por: Kim, In-Cheol, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
por: Haseeb, Muhammad Talha, et al.
Publicado: (2023)

Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy
por: Maizels, Leonid, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Left ventricular volume regulation in heart failure with preserved ejection fraction
por: Kerkhof, Peter L M, et al.
Publicado: (2013)

Left ventricular volume regulation in heart failure with preserved ejection fraction
por: Kerkhof, Peter L M, et al.
Publicado: (2013)

Update of treatment of heart failure with reduction of left ventricular ejection fraction
por: Aronow, Wilbert S.
Publicado: (2016)

Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction
por: Henning, Robert J
Publicado: (2020)

Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction
por: Zhang, Xinxin, et al.
Publicado: (2021)

Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
por: Stencel, Jason, et al.
Publicado: (2023)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022)

Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study
por: Koçak, Ajar, et al.
Publicado: (2023)

Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes
por: Gevaert, Andreas B., et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study
por: Hsiao, Fu-Chih, et al.
Publicado: (2022)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Prognostic implications of left ventricular ejection fraction trajectory changes in heart failure
por: Ding, Zijie, et al.
Publicado: (2023)

Improved Diastolic Function Is Associated With Higher Cardiac Output in Patients With Heart Failure Irrespective of Left Ventricular Ejection Fraction
por: Tobushi, Tomoyuki, et al.
Publicado: (2017)

Prognostic Implications of Changes in Left Ventricular Ejection Fraction and Pulmonary Hypertension in Patients with Heart Failure with Reduced Ejection Fraction
por: Kim, Hyun-Jin
Publicado: (2019)

Female Gender Is Associated with an Increased Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure with Reduced Ejection Fraction
por: Kewcharoen, Jakrin, et al.
Publicado: (2022)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Efficacy and safety of atrial fibrillation ablation in heart failure patients with left ventricular ejection fraction less than 50%
por: Sakamoto, Yusuke, et al.
Publicado: (2023)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Improvement of Left Ventricular Ejection Fraction and Pulmonary Hypertension Are Significant Prognostic Factors in Heart Failure with Reduced Ejection Fraction Patients
por: Kwon, Hee-Jin, et al.
Publicado: (2019)

Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
por: Nauta, J. F., et al.
Publicado: (2021)

Vascular Dysfunction Predicts Future Deterioration of Left Ventricular Ejection Fraction in Patients with Heart Failure with Mildly Reduced Ejection Fraction
por: Kishimoto, Shinji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8kso3kud2vijv197m2shr8pfn5